Mangoceuticals Announces the Launch of “PeachesRx” - a Women's Telehealth Brand Focused on Personalized Wellness and GLP-1 Weight Loss Treatments

Rhea-AI Summary

Mangoceuticals (NASDAQ: MGRX) has announced the launch of PeachesRx, a women's telehealth platform focusing on health and wellness products, initially specializing in GLP-1 receptor agonists for weight loss treatment. The platform will operate through www.PeachesRx.com, offering HIPAA-compliant telemedicine services.

The company is targeting the expanding GLP-1 market, where approximately 70% of weight loss prescriptions are written for women. The global GLP-1 market for weight management is projected to exceed $48 billion by 2030. The women's health market, valued at $49.33 billion in 2024, is expected to reach $68.53 billion by 2030, growing at a 5.1% CAGR.

Studies indicate that over 60% of telehealth users are female, positioning PeachesRx to capture this market segment. The company plans to expand beyond GLP-1 treatments into broader wellness categories, including sexual health, hair growth, and hormone therapy solutions.

Positive

• Entry into the rapidly growing women's health market valued at $49.33 billion
• Targeting GLP-1 weight management market projected to exceed $48 billion by 2030
• Expansion of business model beyond existing men's health platform
• Strategic focus on female demographic that represents 70% of GLP-1 prescriptions

Negative

• Entering a highly competitive market with established players
• Initial focus to GLP-1 treatments may limit immediate revenue potential

Insights

Healthcare Market Analyst

The launch of PeachesRx marks a pivotal strategic shift for Mangoceuticals, potentially transforming the company's market position and growth trajectory. The timing is particularly opportune, coinciding with three important market dynamics:

Market Opportunity and Positioning: The women's health market presents a 5.1x larger opportunity compared to men's health, with projected growth to $68.53 billion by 2030. The focus on GLP-1 treatments is especially strategic, targeting a rapidly expanding segment where women comprise the dominant user base. This positions PeachesRx at the intersection of two high-growth markets: women's health and weight management.

Operational Leverage: By leveraging their existing HIPAA-compliant telehealth infrastructure and operational experience from MangoRx, Mangoceuticals can potentially achieve faster market penetration with lower capital requirements. This approach allows for efficient scaling while maintaining competitive pricing - a important factor in the direct-to-consumer healthcare market.

Growth Catalysts and Risks: The higher telehealth adoption rate among women (60% of users) suggests strong potential for rapid customer acquisition. However, success will largely depend on three critical factors: 1) The company's ability to differentiate its offering in an increasingly competitive telehealth landscape, 2) Maintaining quality control and regulatory compliance while scaling operations, and 3) Effectively managing the working capital requirements of a expanded product portfolio.

The planned expansion into additional women's health categories (sexual health, hair growth, hormone therapy) indicates a broader strategic vision beyond the initial GLP-1 focus. This phased approach allows for market validation and operational refinement before pursuing full-scale expansion.

Dallas, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of men’s wellness products via a secure telemedicine platform under the brand MangoRx, proudly announces the official launch of PeachesRx, an innovative women’s health and wellness brand focused on providing cutting-edge, convenient treatments tailored to women’s unique health needs. These new and innovative women’s health and wellness products will be made available via a secure telemedicine platform located at www.PeachesRx.com.

PeachesRx will debut with a strong focus on compounded GLP-1 receptor agonists—a class of medications proven to aid weight loss by regulating appetite and glucose metabolism. Recent studies show that approximately 70% of GLP-1 prescriptions for weight loss are written for women, reflecting their dominant role in driving the surge in demand for these medications. By introducing its tailored GLP-1 offerings, PeachesRx aims to meet the unique metabolic needs of women while providing an accessible and affordable telehealth-driven solution.

Market demand for GLP-1 weight loss treatments among women is expanding rapidly. Industry projections estimate that the global GLP-1 market for weight management will exceed $48 billion by 2030, with women comprising the majority of users. Additionally, the global women’s health market was valued at $49.33 billion in 2024 and is projected to reach $68.53 billion by 2030, growing at a 5.1% CAGR. Within the U.S. women's telehealth market, growth is fueled by increased awareness, the demand for remote care, and the rise of personalized medicine. PeachesRx is well-positioned to capture this market by delivering GLP-1 solutions tailored to women's health needs, with seamless access through its HIPAA-compliant telemedicine platform.

"The launch of PeachesRx is the natural next step in Mangoceuticals’ expansion as we continue to redefine direct-to-consumer healthcare solutions," said Jacob Cohen, CEO and Founder of Mangoceuticals, who continued, "We’ve seen the success of our telehealth platform for men, and we believe there is an even greater opportunity in women’s health. As we have seen with MangoRx in the men’s health market, brand trust, accessibility, and innovative product offerings have been key to driving MangoRx’s success. PeachesRx will follow this blueprint, ensuring that women can confidently access clinically proven treatments tailored to their needs.”

Women represent a dominant force in telehealth adoption, with studies showing that over 60% of telehealth users are female. More than ever, women are seeking convenient, personalized healthcare solutions, and Peaches aims to revolutionize access by providing affordable, effective, and medically supervised treatments via its secure, HIPAA-compliant telemedicine platform.

"Women’s healthcare has been underserved for too long. With PeachesRx, we are transforming access by providing seamless, confidential, and medically backed care," said Amanda Hammer, COO of Mangoceuticals, who continued, "Our goal is to bring the same level of innovation, affordability, and accessibility that has driven our success in men’s wellness."

Positioned to be a leader in women’s telehealth, PeachesRx combines an intuitive user experience with a commitment to high-quality care, meeting the evolving needs of today’s healthcare consumers. By initially launching with GLP-1 solutions, PeachesRx intends to lay the groundwork for potential future expansion into broader wellness categories, including, but not limited to, sexual health, hair growth, and hormone therapy solutions. The Company plans to grow PeachesRx into a leader in women’s telehealth.

About MangoRx

MangoRx is focused on developing a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com.

About PeachesRx

PeachesRx is focused on developing a variety of women’s health and wellness products and services via a secure telemedicine platform. To date, the PeachesRx has identified weight management as the initial product category for its initial launch. Interested consumers can use PeachesRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through PeachesRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about PeachesRx’s mission and other products, please visit www.PeachesRx.com.

Cautionary Note Regarding Forward-Looking Statements

Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). These forward-looking statements represent the Company’s current expectations or beliefs concerning future events and can generally be identified using statements that include words such as “estimate,” “expects,” “project,” “believe,” “anticipate,” “intend,” “plan,” “foresee,” “forecast,” “likely,” “will,” “target” or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company’s control which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, relating to, among other things: statements about the ability of our trials to demonstrate safety and efficacy of our product candidates, and other positive results; the risk that initial drug results are not predictive of future results or will not be able to be replicated in clinical trials or that such drugs selected for clinical development will not be successful; challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; the Company’s reliance on third parties to conduct its clinical trials; unexpected adverse side effects or inadequate therapeutic efficacy of drug candidates that could limit approval and/or commercialization, or that could result in recalls or product liability claims; uncertainty of commercial success; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim data; including the risk that final results could differ from interim data released; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; the progress of our clinical trials; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes in behavior and spending patterns of purchasers of health care and other of our products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment; the investigation into, outcome of the investigation regarding, and potential lawsuits, claims and actions regarding, a potential stock manipulation scheme relating to the Company’s common stock following the Company’s prior reverse stock split; the outcome of certain outstanding legal matters, claims and allegations, the requirement that the Company spend cash and management’s resources on such matters, even if the Company ultimately prevails in such matters, risks associated with certain counterparties to lawsuits having significantly greater resources than us, settlements we may choose to enter into in the future and the terms thereof, and potential regulatory reviews, inquiries or lawsuits, which are brought about by claims made in private lawsuits; the review and evaluation of strategic transactions and their impact on shareholder value; the process by which the Company engages in evaluation of strategic transactions; the outcome of potential future strategic transactions and the terms thereof; the ability of the Company to raise funding, the terms of such funding, and dilution caused thereby; our ability to meet the continued listing requirements of Nasdaq; our ability to maintain the listing of our common stock on Nasdaq; our ability to commercialize our patent portfolio; our ability to obtain Comisión Federal para la Protección contra Riesgos Sanitarios for our ED product in Mexico, the costs thereof and timing associated therewith; our ability to obtain additional funding and generate revenues to support our operations; risks associated with our products which have not been, and will not be, approved by the U.S. Food and Drug Administration (“ FDA ”) and have not had the benefit of the FDA’s clinical trial protocol which seeks to prevent the possibility of serious patient injury and death; risks that the FDA may determine that the compounding of our products does not fall within the exemption from the Federal Food, Drug, and Cosmetic Act (“ FFDCA Act ”) provided by Section 503A; risks associated with related party relationships and agreements; the effect of data security breaches, malicious code and/or hackers; competition and our ability to create a well-known brand name; changes in consumer tastes and preferences; material changes and/or terminations of our relationships with key parties; significant product returns from customers, product liability, recalls and litigation associated with tainted products or products found to cause health issues; claims, lawsuits and litigation relating to our intellectual property, including allegations that our intellectual property infringes on the intellectual property of others, costs related to any such claims or lawsuits and resources required to expend in connection therewith; our ability to innovate, expand our offerings and compete against competitors which may have greater resources; our significant reliance on related party transactions and risks associated with related party relationships and agreements; the projected size of the potential market for our technologies and products; risks related to the significant number of shares in the public float, our share volume, the effect of sales of a significant number of shares in the marketplace; dilution caused by offerings; conversion of outstanding shares of preferred stock and the rights and preferences thereof, the fact that we have a significant number of outstanding warrants to purchase shares of common stock and other convertible securities, the resale of which underlying shares have been registered under the Securities Act of 1933, as amended, dilution caused by exercises/conversions thereof, overhang related thereto, and decreases in the trading price of our common stock caused by sales thereof; our ability to build and maintain our brands; cybersecurity, information systems and fraud risks and problems with our websites; changes in, and our compliance with, rules and regulations affecting our operations, sales, marketing and/or our products; shipping, production or manufacturing delays; regulations we are required to comply with in connection with our operations, manufacturing, labeling and shipping; our dependency on third-parties to prescribe and compound our products; our ability to establish or maintain relations and/or relationships with third-parties; potential safety risks associated with our products, including the use of ingredients, combination of such ingredients and the dosages thereof; the effects of changing rates of inflation and interest rates, and economic downturns, including potential recessions, as well as macroeconomic, geopolitical, health and industry trends, pandemics, acts of war (including the ongoing Ukraine/Russian conflict and war in Israel) and other large-scale crises; our ability to protect intellectual property rights; our ability to attract and retain key personnel to manage our business effectively; overhang which may reduce the value of our common stock; volatility in the trading price of our common stock; and general consumer sentiment and economic conditions that may affect levels of discretionary customer purchases of the Company’s products, including potential recessions and global economic slowdowns. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements we make in this release are reasonable, we provide no assurance that these plans, intentions or expectations will be achieved. Consequently, you should not consider any such list to be a complete set of all potential risks and uncertainties.

More information on potential factors that could affect the Company’s financial results is included from time to time in the “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and our Quarterly Report on Form 10-Q for the quarter September 30, 2024, and subsequent reports. These filings are available at www.sec.gov and at our website at https://www.mangoceuticals.com/sec-filings . All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Follow MangoRx on social media:

https://www.instagram.com/mango.rx
https://x.com/mango_rx
https://www.facebook.com/MangoRxOfficial

Follow PeachesRx on social media:

https://www.instagram.com/peachesrx/
https://x.com/PeachesRx
https://www.facebook.com/PeachesRx/

FOR INVESTOR RELATIONS
Mangoceuticals Investor Relations
Email: investors@mangorx.com

FAQ

What is the market size for GLP-1 weight management that MGRX is targeting?

The global GLP-1 market for weight management is projected to exceed $48 billion by 2030.

What is the expected growth rate of the women's health market that MGRX's PeachesRx is entering?

The women's health market is projected to grow at a 5.1% CAGR, reaching $68.53 billion by 2030 from $49.33 billion in 2024.

What percentage of GLP-1 weight loss prescriptions are written for women according to MGRX?

Approximately 70% of GLP-1 prescriptions for weight loss are written for women.

What future expansion plans does MGRX have for PeachesRx beyond GLP-1 treatments?

MGRX plans to expand PeachesRx into broader wellness categories, including sexual health, hair growth, and hormone therapy solutions.

What percentage of telehealth users are women according to MGRX's market research?

Over 60% of telehealth users are female according to studies cited by MGRX.